WASHINGTON — President Trump on Tuesday called on the Food and Drug Administration to speed the approval of drugs to treat life-threatening diseases, deriding the agency’s current process as “slow and burdensome.”

In an address to a joint session of Congress, Trump said that the FDA approval process “keeps too many advances … from reaching those in need.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Do not relieve drug makers of the burden of proving their products are efffective and safe. Yes, thalidomide, also Framingham compounding lab. I do not want to be a test animal!

  • Approving Cempra’s solithromycin (an antibiotic) without requiring the extra financially burdensome safety studies the FDA asked for in December (the company just laid off about 67% of their personnel due to this unexpected demand) could be one of the very first “quick wins” that the Trump administration can rapidly accomplish.

    For more info, see: “Cempra’s Solithromycin And The Great FDA Echo Chamber”, on Seeking Alpha. (An account is needed past the first page.)

    • So, you would rather the public complete the safety studies for Cempra by consuming an inadequately characterised drug? I would add that potential hepatotoxicity is not a trifling thing.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy